Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus anlotinib as second-line therapy for advanced thymic carcinoma (phase 2, single-arm)
ChiCTR2500112690Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and anlotinib in thymic carcinoma (TC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Nov 2025; status: recruiting.
02
Drugs
toripalimabanlotinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2500112690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112690.